DCT

4:26-cv-01170

Knoa Pharma LLC v. Humanwell Pharma US Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 4:26-cv-01170, E.D. Mo., 07/23/2026
  • Venue Allegations: Venue is alleged to be proper in the Eastern District of Missouri because Defendant Humanwell is incorporated and maintains its principal place of business in the district. The complaint also alleges that Defendants have consented to venue in a prior case in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for generic versions of the opioid pain medication HYSINGLA® ER constitutes an act of infringement of four U.S. patents related to tamper-resistant, controlled-release drug formulations.
  • Technical Context: The patents relate to abuse-deterrent formulations for opioid analgesics, a technology area of significant public health and commercial importance aimed at making prescription opioids more difficult to crush, dissolve, or otherwise tamper with for misuse.
  • Key Procedural History: This action was filed under the Hatch-Waxman Act within 45 days of Plaintiffs' receipt of a Paragraph IV certification notice letter from Defendant Humanwell, triggering an automatic 30-month stay of FDA approval for the generic product. The asserted patents were previously owned by Purdue Pharma L.P. and were transferred to the Plaintiffs on May 1, 2026. The complaint also notes that Defendants have previously consented to jurisdiction and venue in the district in a separate litigation.

Case Timeline

Date Event
2010-12-22 U.S. Patent 8,808,740 Priority Date
2012-06-28 '740 Patent Application Becomes Public
2014-07-02 '740 Patent Allowed Claims Become Public
2014-07-14 '740 Patent Issue Fee Paid
2014-08-19 U.S. Patent 8,808,740 Issues
2014-11-21 '740 Patent Submitted for Orange Book Listing
2016-02-17 U.S. Patent 9,872,837 Priority Date
2016-08-25 '837 Patent Application Becomes Public
2017-01-24 U.S. Patent 9,770,416 Priority Date
2017-01-24 U.S. Patent 9,775,809 Priority Date
2017-05-11 '416 and '809 Patent Applications Become Public
2017-08-07 '416 and '809 Patent Allowed Claims Become Public
2017-08-10 '416 and '809 Patent Issue Fees Paid
2017-09-26 U.S. Patent 9,770,416 Issues
2017-09-27 '416 Patent Submitted for Orange Book Listing
2017-10-03 U.S. Patent 9,775,809 Issues
2017-10-04 '809 Patent Submitted for Orange Book Listing
2017-11-08 '837 Patent Allowed Claims Become Public
2017-11-20 '837 Patent Issue Fee Paid
2018-01-23 U.S. Patent 9,872,837 Issues
2018-01-23 '837 Patent Submitted for Orange Book Listing
2026-05-01 Asserted Patents Transferred to Plaintiffs
2026-06-09 Defendants Send Paragraph IV Notice Letter to Plaintiffs
2026-07-23 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,808,740 - "Encased Tamper Resistant Controlled Release Dosage Forms", issued August 19, 2014

The Invention Explained

  • Problem Addressed: The patent addresses the problem of opioid abuse, where abusers tamper with controlled-release dosage forms (e.g., by crushing or dissolving) to enable rapid administration of the entire dose, which can be dangerous or fatal '740 Patent, col. 1:24-34
  • The Patented Solution: The invention is a solid oral dosage form that is mechanically strong enough to resist tampering. Specifically, the tablet can be physically deformed or "flattened" to a fraction of its original thickness without breaking '740 Patent, col. 5:3-7 This physical resilience is designed to prevent crushing, while the formulation is also engineered to maintain its controlled-release properties even if deformed, thus deterring dose-dumping '740 Patent, col. 5:7-14
  • Technical Importance: This approach provided a physically robust dosage form that could deter common methods of abuse (e.g., crushing for snorting or dissolving for injection) while still delivering the therapeutic agent over an extended period as intended.

Key Claims at a Glance

  • The complaint asserts independent claim 91 Compl. ¶42
  • Essential elements of claim 91 include:
    • A solid controlled release dosage form with a therapeutically effective amount of hydrocodone and a controlled release excipient.
    • The amount of hydrocodone released is "proportional within 20% to elapsed time from 8 to 24 hours" under specific in-vitro test conditions.
    • The dosage form "can be flattened without breaking," with the flattened thickness being "no more than about 20% of the thickness" before flattening.
    • The drug release at 0.5 hours from a flattened form "deviates no more than about 20% points" from a non-flattened form under the same test conditions.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent but alleges the accused products are covered by "one or more claims" Compl. ¶43

U.S. Patent No. 9,872,837 - "Tamper Resistant Controlled Release Dosage Forms", issued January 23, 2018

The Invention Explained

  • Problem Addressed: Like the '740 patent, the '837 patent addresses the problem of tampering with opioid dosage forms to achieve rapid dose release '837 Patent, col. 1:24-34
  • The Patented Solution: The solution involves a specific formulation and manufacturing process. The active ingredient is dispersed in a matrix of high-molecular-weight polyethylene oxide (PEO), which is then "cured" by heating it at a specified temperature for a minimum duration '837 Patent, col. 11:53-56 This curing process is described as creating the tamper-resistant properties by, for example, at least partially melting the PEO '837 Patent, col. 21:18-30 The invention combines this manufacturing method with specific physical resilience and drug release characteristics.
  • Technical Importance: This invention focuses on the role of thermal processing ("curing") of a PEO matrix to create a dosage form with specific, measurable tamper-resistant and pharmacokinetic properties.

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶53
  • Essential elements of claim 1 include:
    • A solid tamper-resistant controlled release dosage form with hydrocodone dispersed in a PEO matrix of a specified average molecular weight (300,000 to 10,000,000).
    • The dosage form is "cured at a temperature of at least 60° C. for at least 1 minute."
    • A multi-point dissolution profile: release at 2 hours is <25%, at 4 hours is 10%-30%, at 8 hours is 20%-60%, at 12 hours is 40%-90%, and at 18 hours is >70%.
    • The dosage form can be flattened to no more than 20% of its original thickness without breaking.
    • The release at 0.5 hours from a flattened form deviates no more than 20% points from a non-flattened form.
  • The complaint alleges the accused products are covered by "one or more claims," including at least claim 1 (Compl. ¶54).

U.S. Patent No. 9,770,416 - "Tamper Resistant Dosage Forms", issued September 26, 2017

Technology Synopsis

This patent describes a tamper-resistant pharmaceutical composition based on a high-molecular-weight PEO matrix. The invention is characterized by a specific manufacturing process involving shaping by compression, followed by air curing with heated air without compression, which causes the dosage form to expand and harden, resulting in specific physical properties like high hardness and decreased density '416 Patent, col. 1:1-2:4 '416 Patent, claim 1

Asserted Claims

The complaint asserts independent claim 1 Compl. ¶66

Accused Features

The complaint alleges that the Humanwell ANDA Products are a pharmaceutical composition containing an opioid in a PEO matrix that is compression shaped and air cured, resulting in partial melting of the PEO, expansion, and hardening, thereby infringing claim 1 (Compl. ¶67).

U.S. Patent No. 9,775,809 - "Tamper Resistant Dosage Forms", issued October 3, 2017

Technology Synopsis

This patent is directed to a tamper-resistant pharmaceutical composition comprising an opioid in a high-molecular-weight PEO matrix. The inventive process involves shaping the composition by compression and then air curing it with heated air at a temperature above the PEO's softening temperature, which causes the PEO to comprise at least 30% of the dosage form's weight '809 Patent, col. 1:1-2:13 '809 Patent, claim 1

Asserted Claims

The complaint asserts independent claim 1 Compl. ¶79

Accused Features

The complaint alleges the Humanwell ANDA Products contain hydrocodone in a high-molecular-weight PEO matrix that is compression shaped and air cured above the PEO's softening temperature, with the PEO comprising at least 30% of the dosage form's weight, thereby infringing claim 1 (Compl. ¶80).

III. The Accused Instrumentality

Product Identification

The accused products are generic hydrocodone bitartrate extended-release tablets in 20 mg, 30 mg, 40 mg, and 60 mg dosages, for which Defendants seek FDA approval via ANDA No. 215216 (the "Humanwell ANDA Products") Compl. ¶12 Compl. ¶38

Functionality and Market Context

The Humanwell ANDA Products are intended to be generic equivalents to Plaintiffs' HYSINGLA® ER product, an FDA-approved extended-release tablet for managing severe pain Compl. ¶27 Compl. ¶39 The complaint alleges the accused products are solid, controlled-release dosage forms containing hydrocodone bitartrate as the active ingredient Compl. ¶38 Compl. ¶43 The basis for the infringement action is the filing of the ANDA itself, which seeks approval to market these products as bioequivalent to HYSINGLA® ER prior to the expiration of the Asserted Patents Compl. ¶1 Compl. ¶39 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

8,808,740 Infringement Allegations

Claim Element (from Independent Claim 91) Alleged Infringing Functionality Complaint Citation Patent Citation
A solid controlled release dosage form comprising: a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a controlled release excipient; On information and belief, the Humanwell ANDA Products are a solid controlled release dosage form with a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a controlled release excipient. ¶43 col. 5:21-24
wherein the amount of hydrocodone or salt thereof released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution... On information and belief, the amount of hydrocodone or salt thereof released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution... ¶43 col. 5:29-37
the dosage form can be flattened without breaking, wherein the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening; and On information and belief, the dosage form can be flattened without breaking, and the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening. ¶43 col. 5:3-7
the amount of hydrocodone or salt thereof released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form as measured by an in-vitro dissolution... On information and belief, the amount of hydrocodone or salt thereof released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form as measured by an in-vitro dissolution... ¶43 col. 5:7-14
  • Identified Points of Contention: The infringement allegations for the '740 Patent rely entirely on quantitative physical and chemical properties. The central dispute will likely be evidentiary: does the product described in Defendants' ANDA actually exhibit the claimed properties (e.g., flattenability, specific release profiles) when measured according to the protocols defined in the patent? The complaint makes these allegations "on information and belief," suggesting Plaintiffs have not yet tested the accused product, which is typical at this stage of an ANDA litigation.

9,872,837 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A solid tamper resistant controlled release dosage form comprising: hydrocodone or a pharmaceutically acceptable salt thereof dispersed in a matrix material comprising polyethylene oxide having an average molecular weight from about 300,000 to about 10,000,000... On information and belief, the Humanwell ANDA Products are a solid tamper resistant controlled release dosage form with hydrocodone...dispersed in a matrix material comprising polyethylene oxide having an average molecular weight from about 300,000 to about 10,000,000... ¶54 col. 11:23-28
wherein the dosage form is cured at a temperature of at least 60° C. for at least 1 minute; On information and belief, the dosage form is cured at a temperature of at least 60°C for at least 1 minute. ¶54 col. 11:29-31
wherein the amount of hydrocodone...released from the dosage form...at 2 hours is less than about 25%, at 4 hours is from about 10% to about 30%, at 8 hours is from about 20% to about 60%, at 12 hours is from about 40% to about 90%, and at 18 hours is greater than about 70%; and On information and belief, the amount of hydrocodone...released from the dosage form...at 2 hours is less than about 25%, at 4 hours is from about 10% to about 30%, at 8 hours is from about 20% to about 60%, at 12 hours is from about 40% to about 90%, and at 18 hours is greater than about 70%. ¶54 col. 12:1-8
wherein the dosage form can be flattened without breaking, wherein the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening; and On information and belief, the dosage form can be flattened without breaking, and the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening. ¶54 col. 12:9-13
the amount of hydrocodone...released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form... On information and belief, the amount of hydrocodone...released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form... ¶54 col. 12:14-20
  • Identified Points of Contention: A key question for the '837 Patent will be whether the process used to make the Humanwell ANDA Products falls within the scope of the term "cured." The complaint alleges the accused product is cured, but this is a process limitation that may be a point of dispute. Further, the claim recites a highly specific, multi-point dissolution profile, and infringement will depend on whether the accused product meets every one of those constraints. The complaint notes that Defendants' Notice Letter did not include non-infringement arguments for this patent, which may suggest Defendants' primary defense will be invalidity rather than non-infringement (Compl. ¶56).

V. Key Claim Terms for Construction

For U.S. Patent 8,808,740

  • The Term: "flattened without breaking"
  • Context and Importance: This term defines the core physical tamper-resistance feature of the claimed invention. The dispute will center on whether the accused product exhibits this specific property. Practitioners may focus on this term because the patent's specification provides a highly detailed, instrument-specific testing protocol for measuring it ('740 Patent, col. 27:3-23), which could form the basis for a narrow construction.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language itself is functional ("can be flattened without breaking"), which could support an argument that any method of deformation that does not result in fragmentation meets the limitation, regardless of the specific testing apparatus used.
    • Evidence for a Narrower Interpretation: The specification describes a specific test using a "Texture Analyzer" with a "stainless steel ball probe" to determine the breaking strength ('740 Patent, col. 27:3-23). Defendants may argue that this detailed description limits the claim to tablets that resist breaking under this specific test, while Plaintiffs may argue it is merely an exemplary method.

For U.S. Patent 9,872,837

  • The Term: "cured"
  • Context and Importance: This is a critical process step that allegedly imparts the tamper-resistant qualities to the dosage form. The definition of "cured" will determine whether the manufacturing process for the accused product infringes.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim itself provides a broad definition: "at a temperature of at least 60° C. for at least 1 minute" ('837 Patent, claim 1). Plaintiffs may argue that any heating process that meets these minimum time and temperature parameters constitutes "curing."
    • Evidence for a Narrower Interpretation: The specification provides extensive detail on the curing process, defining it as a step where the PEO at least partially melts ('837 Patent, col. 21:18-22) and describing specific temperature profiles, such as "plateau-like" or "parabolic" shapes over time ('837 Patent, col. 22:3-4; col. 22:31-33). Defendants may argue that "cured" requires not just heating, but achieving one of these specific thermal profiles to effect the partial melting of the PEO as described in the detailed description.

VI. Other Allegations

  • Indirect Infringement: The complaint's primary infringement allegation is based on 35 U.S.C. § 271(e)(2), which defines the submission of an ANDA seeking approval to market a drug claimed in a patent as an act of infringement (Compl. ¶46; Compl. ¶59; Compl. ¶72; Compl. ¶85). The complaint alleges Defendants had knowledge of the patents at least because they are listed in the FDA's Orange Book for HYSINGLA® (Compl. ¶44; Compl. ¶57; Compl. ¶70; Compl. ¶83). While the complaint focuses on this artificial act of infringement, it also anticipates future acts of direct infringement under § 271(a) upon FDA approval (Compl. ¶47; Compl. ¶60; Compl. ¶73; Compl. ¶86).
  • Willful Infringement: Plaintiffs request a finding of willful infringement (Request for Relief (f)). The factual basis alleged is Defendants' knowledge of the Asserted Patents prior to and during the ANDA filing process, based on the patents' publication history and their listing in the Orange Book (Compl. ¶44; Compl. ¶45; Compl. ¶57; Compl. ¶58; Compl. ¶70; Compl. ¶71; Compl. ¶83; Compl. ¶84). The complaint alleges that despite this knowledge, Defendants proceeded with their intent to market the infringing products (Compl. ¶44; Compl. ¶57; Compl. ¶70; Compl. ¶83).

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of evidentiary proof: does the formulation described in Defendants' ANDA, which Plaintiffs have likely not yet tested, actually possess the highly specific and quantitative physical properties (e.g., flattenability to less than 20% thickness without breaking) and multi-point dissolution profiles required by the asserted claims? The case will likely devolve into a battle of competing expert analyses of the accused product.
  • A second key question will be one of claim construction: can the term "cured," as used in the '837, '416, and '809 patents, be limited to the detailed thermal profiles and partial-melting mechanisms described in the specification, or does it simply mean heating at a minimum temperature for a minimum time as recited in the claims? The outcome of this construction will be critical to determining infringement of the process-related limitations.
  • A final question centers on infringement theory: for the '837, '416, and '809 patents, the complaint states that Defendants' Paragraph IV notice letter "does not contend or make non-infringement arguments" (Compl. ¶56; Compl. ¶69; Compl. ¶82). This raises the question of whether Defendants will primarily rely on an invalidity defense for these patents, potentially simplifying the infringement analysis if the patents survive the validity challenge.
Loading Complaint